Skip to main content

PharmaEssentia

PharmaEssentia Corporation is a Taiwan-based biopharmaceutical company focused on the development, manufacturing, and commercialization of biologic therapies for hematology and oncology indications. The company utilizes its proprietary pegylation technology platform to produce long-acting proteins, with its lead product targeted at myeloproliferative neoplasms such as polycythemia vera. Primary revenues are generated from global product sales of prescription biologics, licensing agreements, and clinical research partnerships. PharmaEssentia serves hospitals, specialty clinics, hematology specialists, and cancer treatment centers across the United States, Europe, Taiwan, and other Asian markets. The enterprise holds an established international market position as an innovative commercial-stage biopharmaceutical manufacturer. PharmaEssentia Corporation is headquartered in Taipei, Taiwan, and its common shares are listed on the Taipei Exchange.

17 of the funds FundTelligence covers report a position in PharmaEssentia.

Legal name
PharmaEssentia Corp
Sector
Health Care
Country
Taiwan
Funds holding it
17

Funds holding PharmaEssentia

Showing the 8 largest of 17 funds holding it.

Loading...